| For: | Quentin V, Singh M, Nguyen LS. A review of potential mechanisms and uses of SGLT2 inhibitors in ischemia-reperfusion phenomena. World J Diabetes 2022; 13(9): 683-695 [PMID: 36188147 DOI: 10.4239/wjd.v13.i9.683] |
|---|---|
| URL: | https://www.wjgnet.com/1948-9358/full/v13/i9/683.htm |
| Number | Citing Articles |
| 1 |
Guifang Chen, Yujiao Zhu, Junmei Lu, Yihua Bei. Cardiometabolic Dynamics. 2026; doi: 10.1016/B978-0-443-34186-1.00014-1
|
| 2 |
Danúbia Silva dos Santos, Lauro Thiago Turaça, Keyla Cristiny da Silva Coutinho, Raiana Andrade Quintanilha Barbosa, Juliano Zequini Polidoro, Tais Hanae Kasai-Brunswick, Antonio Carlos Campos de Carvalho, Adriana Castello Costa Girardi. Empagliflozin reduces arrhythmogenic effects in rat neonatal and human iPSC-derived cardiomyocytes and improves cytosolic calcium handling at least partially independent of NHE1. Scientific Reports 2023; 13(1) doi: 10.1038/s41598-023-35944-5
|
| 3 |
Cong Ma, Pangbo Yang, Rumeng Du, Simin Yang, Zhiwei Xu. Molecular Mechanisms and Clinical Applications of SGLT2 Inhibitors in Cardiovascular Diseases. Journal of Cardiovascular Translational Research 2026; 19(1) doi: 10.1007/s12265-026-10794-4
|
| 4 |
Fatemeh Chichagi, Elahe Meftah, Rahem Rahmati, Fatemeh Zarimeidani, Arian Tavasol, Kimiya Ghanbari Mardasi, Negar Omidi. Cardiopulmonary Remodeling In Nondiabetic Patients with Systolic Heart Failure Using Sodium-Glucose Cotransporter 2 Inhibitors: An Updated
Systematic Review and Meta-Analysis of Randomized Clinical Trials. Current Cardiology Reviews 2026; 22(4) doi: 10.2174/011573403X377983250904004839
|
| 5 |
Shan Li, Qimeng Wang, Mingming Wang, Rongyun Su, Yinghui Wang, Xiangchun Liu, Qingzhen Liu, Gang Liu. Ertugliflozin Mitigates Renal Ischemia-Reperfusion Injury through the Downregulation of HIF-1α Expression. American Journal of Nephrology 2025; 57(3) doi: 10.1159/000547539
|
| 6 |
Megan Young, Sanushi Dambure, Fenn Cullen, Kimia Jarrah, Lana McClements, Zenouska Ramchunder, Dunja Aksentijevic. Dual SGLT1/2 inhibition with sotagliflozin improves cardiac function and metabolism in type 2 diabetic mice. npj Metabolic Health and Disease 2026; 4(1) doi: 10.1038/s44324-026-00119-z
|
| 7 |
Tomoya Okamoto, Hiromitsu Sasaki, Yudai Morisaki, Shohei Yokoyama, Yasuhiko Saito, Ichiro Nakagawa. Post-ischemic sodium glucose cotransporter inhibition attenuates ischemia–reperfusion injury via regulation of mitochondrial membrane potential. Journal of Cerebral Blood Flow & Metabolism 2026; doi: 10.1177/0271678X261468880
|
| 8 |
Bing Zhang, Liufei Deng. Application of SGLT-2 inhibitors in non-diabetic CKD: mechanisms, efficacy, and safety. Frontiers in Medicine 2025; 12 doi: 10.3389/fmed.2025.1574693
|
| 9 |
Wangde Dai, Rashid Alavi, Jiajun Li, Juan Carreno, Niema M. Pahlevan, Robert A. Kloner. Empagliflozin demonstrates neuroprotective and cardioprotective effects by reducing ischemia/reperfusion damage in rat models of ischemic stroke and myocardial infarction. Scientific Reports 2025; 15(1) doi: 10.1038/s41598-025-93483-7
|